List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1694897/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature, 1993, 363, 418-423.	13.7	1,823
2	Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Molecular Cell, 2005, 17, 393-403.	4.5	1,639
3	Shape Complementarity at Protein/Protein Interfaces. Journal of Molecular Biology, 1993, 234, 946-950.	2.0	1,231
4	Conformations of immunoglobulin hypervariable regions. Nature, 1989, 342, 877-883.	13.7	1,199
5	BCL-2 family antagonists for cancer therapy. Nature Reviews Drug Discovery, 2008, 7, 989-1000.	21.5	549
6	Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis. Cell, 2013, 152, 519-531.	13.5	491
7	Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature, 1976, 264, 415-420.	13.7	423
8	The structural biology of type I viral membrane fusion. Nature Reviews Molecular Cell Biology, 2003, 4, 309-319.	16.1	408
9	The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins: Structure, Function and Bioinformatics, 1992, 14, 327-332.	1.5	399
10	Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6217-6222.	3.3	397
11	Structure-guided design of a selective BCL-XL inhibitor. Nature Chemical Biology, 2013, 9, 390-397.	3.9	324
12	To Trigger Apoptosis, Bak Exposes Its BH3 Domain and Homodimerizes via BH3:Groove Interactions. Molecular Cell, 2008, 30, 369-380.	4.5	296
13	The Dendritic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments. Immunity, 2012, 36, 646-657.	6.6	272
14	Electrostatic complementarity at protein/protein interfaces 1 1Edited by B. Honig. Journal of Molecular Biology, 1997, 268, 570-584.	2.0	255
15	Discovery of a Potent and Selective BCL-X _L Inhibitor with <i>in Vivo</i> Activity. ACS Medicinal Chemistry Letters, 2014, 5, 1088-1093.	1.3	242
16	Crystal and Molecular Structure of a Dimer Composed of the Variable Portions of the Bence-Jones Protein REI. FEBS Journal, 1974, 45, 513-524.	0.2	220
17	Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure, 1998, 6, 735-746.	1.6	210
18	The Structure of the Fusion Glycoprotein of Newcastle Disease Virus Suggests a Novel Paradigm for the Molecular Mechanism of Membrane Fusion. Structure, 2001, 9, 255-266.	1.6	201

#	Article	IF	CITATIONS
19	Structure of the Haemagglutinin-neuraminidase from Human Parainfluenza Virus Type III. Journal of Molecular Biology, 2004, 335, 1343-1357.	2.0	200
20	Dihydropyrancarboxamides Related to Zanamivir:Â A New Series of Inhibitors of Influenza Virus Sialidases. 2. Crystallographic and Molecular Modeling Study of Complexes of 4-Amino-4H-pyran-6-carboxamides and Sialidase from Influenza Virus Types A and B. Journal of Medicinal Chemistry, 1998, 41, 798-807.	2.9	197
21	Threeâ€dimensional structure of the complex of 4â€guanidinoâ€Neu5Ac2en and influenza virus neuraminidase. Protein Science, 1995, 4, 1081-1087.	3.1	176
22	Mutations in a Conserved Residue in the Influenza Virus Neuraminidase Active Site Decreases Sensitivity to Neu5Ac2en-Derived Inhibitors. Journal of Virology, 1998, 72, 2456-2462.	1.5	175
23	Structure of the human antibody molecule kol (immunoglobulin G1): An electron density map at 5 Ã resolution. Journal of Molecular Biology, 1976, 100, 257-278.	2.0	160
24	The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Structure, 1994, 2, 733-746.	1.6	157
25	A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. Journal of Cell Biology, 2008, 180, 341-355.	2.3	157
26	Generation and Characterization of an Influenza Virus Neuraminidase Variant with Decreased Sensitivity to the Neuraminidase-Specific Inhibitor 4-Guanidino-Neu5Ac2en. Virology, 1995, 214, 475-484.	1.1	155
27	Evaluation of Diverse α/β-Backbone Patterns for Functional α-Helix Mimicry: Analogues of the Bim BH3 Domain. Journal of the American Chemical Society, 2012, 134, 315-323.	6.6	144
28	Highâ€Resolution Structural Characterization of a Helical α/βâ€Peptide Foldamer Bound to the Antiâ€Apoptotic Protein Bclâ€x _L . Angewandte Chemie - International Edition, 2009, 48, 4318-4322.	7.2	143
29	Bak Core and Latch Domains Separate during Activation, and Freed Core Domains Form Symmetric Homodimers. Molecular Cell, 2014, 55, 938-946.	4.5	140
30	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nature Communications, 2019, 10, 2385.	5.8	139
31	Structural Studies of the Resistance of Influenza Virus Neuramindase to Inhibitors. Journal of Medicinal Chemistry, 2002, 45, 2207-2212.	2.9	125
32	A Structural Viral Mimic of Prosurvival Bcl-2:ÂAÂPivotal Role for Sequestering ProapoptoticÂBax and Bak. Molecular Cell, 2007, 25, 933-942.	4.5	125
33	The three-dimensional structure of N -acetylneuraminate lyase from Escherichia coli. Structure, 1994, 2, 361-369.	1.6	123
34	Crystallographic Structural Studies of a Human Fc Fragment. II. A Complete Model Based on a Fourier Map at 3.5 A Resolution. Hoppe-Seyler's Zeitschrift FA1⁄4r Physiologische Chemie, 1976, 357, 1421-1434.	1.7	120
35	Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. FEBS Journal, 1994, 221, 151-157.	0.2	115
36	Targeting BCL-2-like Proteins to Kill Cancer Cells. Trends in Cancer, 2016, 2, 443-460.	3.8	114

#	Article	IF	CITATIONS
37	Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1. PLoS Pathogens, 2010, 6, e1001236.	2.1	99
38	Analysis of inhibitor binding in influenza virus neuraminidase. Protein Science, 2001, 10, 689-696.	3.1	97
39	Mutation to Bax beyond the BH3 Domain Disrupts Interactions with Pro-survival Proteins and Promotes Apoptosis. Journal of Biological Chemistry, 2011, 286, 7123-7131.	1.6	96
40	Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands. Journal of Biological Chemistry, 2009, 284, 30508-30517.	1.6	79
41	New Antivirals and Drug Resistance. Annual Review of Biochemistry, 2009, 78, 95-118.	5.0	65
42	Crystal structure of the human Fab fragment Kol and its comparison with the intact Kol molecule. Journal of Molecular Biology, 1978, 121, 441-459.	2.0	62
43	Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-X _L . Journal of Medicinal Chemistry, 2013, 56, 5514-5540.	2.9	60
44	Recombinant antineuraminidase single chain antibody: Expression, characterization, and crystallization in complex with antigen. Proteins: Structure, Function and Bioinformatics, 1993, 16, 57-63.	1.5	58
45	Novel inhibitors of influenza sialidases related to GG167 structure-activity, crystallographic and Molecular dynamics studies with 4H-pyran-2-carboxylic acid 6-carboxamides. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2931-2936.	1.0	58
46	Conversion of Bim-BH3 from Activator to Inhibitor of Bak through Structure-Based Design. Molecular Cell, 2017, 68, 659-672.e9.	4.5	57
47	Crystallographic Structural Studies of a Human Fc-Fragment. I. An Electron-Density Map at 4 Ã Resolution and a Partial Model. Hoppe-Seyler's Zeitschrift Für Physiologische Chemie, 1976, 357, 435-446.	1.7	56
48	Structural Basis of Bclâ€x _L Recognition by a BH3â€Mimetic α/βâ€Peptide Generated by Sequenceâ€Based Design. ChemBioChem, 2011, 12, 2025-2032.	1.3	56
49	Discovery and molecular characterization of a Bcl-2–regulated cell death pathway in schistosomes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6999-7003.	3.3	53
50	BAK core dimers bind lipids and can be bridged by them. Nature Structural and Molecular Biology, 2020, 27, 1024-1031.	3.6	49
51	Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 669-673.	1.0	46
52	Sheeppox Virus SPPV14 Encodes a Bcl-2-Like Cell Death Inhibitor That Counters a Distinct Set of Mammalian Proapoptotic Proteins. Journal of Virology, 2012, 86, 11501-11511.	1.5	41
53	Physiological restraint of Bak by Bcl-x _L is essential for cell survival. Genes and Development, 2016, 30, 1240-1250.	2.7	40
54	Structure of Leishmania mexicana Phosphomannomutase Highlights Similarities with Human Isoforms. Journal of Molecular Biology, 2006, 363, 215-227.	2.0	38

#	Article	IF	CITATIONS
55	Structural Insight into BH3 Domain Binding of Vaccinia Virus Antiapoptotic F1L. Journal of Virology, 2014, 88, 8667-8677.	1.5	37
56	Structure-Guided Rescaffolding of Selective Antagonists of BCL-X _L . ACS Medicinal Chemistry Letters, 2014, 5, 662-667.	1.3	37
57	Structural Insights into the Protease-like Antigen Plasmodium falciparum SERA5 and Its Noncanonical Active-Site Serine. Journal of Molecular Biology, 2009, 392, 154-165.	2.0	35
58	EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins. Cell Death and Differentiation, 2020, 27, 1554-1568.	5.0	35
59	Ensemble Properties of Bax Determine Its Function. Structure, 2018, 26, 1346-1359.e5.	1.6	34
60	The Functional Differences between Pro-survival and Pro-apoptotic B Cell Lymphoma 2 (Bcl-2) Proteins Depend on Structural Differences in Their Bcl-2 Homology 3 (BH3) Domains. Journal of Biological Chemistry, 2014, 289, 36001-36017.	1.6	33
61	De-Novo Designed Library of Benzoylureas as Inhibitors of BCL-X _L : Synthesis, Structural and Biochemical Characterization. Journal of Medicinal Chemistry, 2014, 57, 1323-1343.	2.9	33
62	Three-dimensional structures of single-chain Fv-neuraminidase complexes. Journal of Molecular Biology, 1998, 279, 901-910.	2.0	32
63	Cloning, Expression, and Crystallization of the Fusion Protein of Newcastle Disease Virus. Virology, 2001, 290, 290-299.	1.1	31
64	Preliminary crystallographic data for a basic copper-containing protein from cucumber seedlings. Journal of Molecular Biology, 1977, 112, 649-650.	2.0	30
65	The Structure of Cucurbitin: Subunit Symmetry and Organization in situ. FEBS Journal, 1980, 103, 585-588.	0.2	30
66	A small molecule interacts with VDAC2 to block mouse BAK-driven apoptosis. Nature Chemical Biology, 2019, 15, 1057-1066.	3.9	30
67	Novel Bcl-2 Homology-3 Domain-like Sequences Identified from Screening Randomized Peptide Libraries for Inhibitors of the Pro-survival Bcl-2 Proteins. Journal of Biological Chemistry, 2009, 284, 31315-31326.	1.6	29
68	Modelling the structure of the fusion protein from human respiratory syncytial virus. Protein Engineering, Design and Selection, 2002, 15, 365-371.	1.0	28
69	Structure of glyceraldehyde-3-phosphate dehydrogenase fromPlasmodium falciparum. Acta Crystallographica Section D: Biological Crystallography, 2005, 61, 1213-1221.	2.5	28
70	Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. Diabetes Care, 2017, 40, 1494-1499.	4.3	28
71	Vaccinia Virus F1L Interacts with Bak Using Highly Divergent Bcl-2 Homology Domains and Replaces the Function of Mcl-1. Journal of Biological Chemistry, 2010, 285, 4695-4708.	1.6	26
72	Structure of detergent-activated BAK dimers derived from the inert monomer. Molecular Cell, 2021, 81, 2123-2134.e5.	4.5	26

#	Article	IF	CITATIONS
73	Crystal Structure of a BCL-W Domain-Swapped Dimer: Implications for the Function of BCL-2 Family Proteins. Structure, 2011, 19, 1467-1476.	1.6	25
74	Zanamivir: an influenza virus neuraminidase inhibitor. Expert Review of Anti-Infective Therapy, 2005, 3, 191-199.	2.0	24
75	Preliminary crystallographic data for a copper-containing protein, plastocyanin. Journal of Molecular Biology, 1977, 110, 187-189.	2.0	23
76	Tethered Neuraminidase Inhibitors That Bind an Influenza Virus: A First Step Towards a Diagnostic Method for Influenza. Angewandte Chemie - International Edition, 2003, 42, 3118-3121.	7.2	22
77	The Function of the Hypothalamic–Pituitary–Adrenal Axis in Alzheimer's Disease. British Journal of Psychiatry, 1994, 165, 650-657.	1.7	18
78	The use of rotation and translation functions in the interpretation of low resolution electron density maps. Journal of Molecular Biology, 1976, 100, 278-282.	2.0	13
79	The disulphide bonds of an Asian influenza virus neuraminidase. FEBS Letters, 1983, 153, 29-33.	1.3	12
80	NMR studies of interactions between Bax and BH3 domain-containing peptides in the absence and presence of CHAPS. Archives of Biochemistry and Biophysics, 2014, 545, 33-43.	1.4	11
81	The Trypanosomal Trans-Sialidase. Structure, 2002, 10, 1466-1468.	1.6	10
82	lon currents through Kir potassium channels are gated by anionic lipids. Nature Communications, 2022, 13, 490.	5.8	9
83	Insights into pituitary tumorigenesis: from Sanger sequencing to next-generation sequencing and beyond. Expert Review of Endocrinology and Metabolism, 2019, 14, 399-418.	1.2	8
84	Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X _L and BCL-2. Journal of Medicinal Chemistry, 2021, 64, 5447-5469.	2.9	5
85	Structure of the BAK-activating antibody 7D10 bound to BAK reveals an unexpected role for the α1-α2 loop in BAK activation. Cell Death and Differentiation, 2022, 29, 1757-1768.	5.0	4
86	Specificity and Promiscuity in Protein - Ligand and Protein - Protein Interactions. Australian Journal of Chemistry, 2003, 56, 763.	0.5	3
87	Early days in drug discovery by crystallography – personal recollections. Acta Crystallographica Section A: Foundations and Advances, 2013, 69, 60-62.	0.3	3
88	Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2. ACS Infectious Diseases, 2021, 7, 1143-1163.	1.8	3
89	Crystallography and New Medicines: Examples from Influenza and Cell Death. Australian Journal of Chemistry, 2014, 67, 1720.	0.5	2
90	Intense focal pituitary FDG uptake due to intravascular large B ell lymphoma in pyrexia of unknown origin. American Journal of Hematology, 2016, 91, 1167-1168.	2.0	2

#	Article	IF	CITATIONS
91	The Bak core dimer focuses triacylglycerides in the membrane. Biophysical Journal, 2022, 121, 347-360.	0.2	1
92	Vale Colin Ward—A Leader in Receptor Structural Biology. Frontiers in Endocrinology, 2017, 8, 95.	1.5	0
93	Colin Wesley Ward 1943–2017. Historical Records of Australian Science, 2018, 29, 191.	0.3	Ο